Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.49 |
| ▸ | WNT3A | P56704 | 3/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4912576 | 0.98 | CES2 (0.52) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL7521813 | 0.85 | CES2 (0.40) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL225566 | 0.83 | CES2 (0.55) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL18171695 | 0.82 | KMT2A (0.68) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL1165353 | 0.79 | CES2 (0.45) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL5200046 | 0.79 | CES2 (0.59) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL253276 | 0.78 | CES2 (0.64) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL2470002 | 0.78 | CTNNB1 (0.71) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL29355245 | 0.78 | CES2 (0.64) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL5668969 | 0.78 | CES2 (0.44) | CES2CES1LMNAL3MBTL1NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3925955-A1 | METHOD FOR ASYMMETRICALLY PREPARING NICOTINE | SHENZHEN CATALYS TECHNOLOGY CO., LTD. (CN) | 2021-12-22 | — | — | EP | claimed |
| US-20080255364-A1 | Method For The Production A-Chloroalkylpyridyl Ketones And/Or The Hydrochlorides Thereof | BASF AKTIENGESELLSCHAFT (DE) | 2008-10-16 | — | — | US | claimed |
| EP-0299277-B1 | Process for the preparation of substituted pyridyl-alkyl ketones | BAYER AG (DE) | 1995-10-18 | — | — | EP | claimed |
| JP-1031767-A | — | — | None | — | — | JP | disclosed |
| EP-3925955-A1 | METHOD FOR ASYMMETRICALLY PREPARING NICOTINE | SHENZHEN CATALYS TECHNOLOGY CO., LTD. (CN) | 2021-12-22 | — | — | EP | disclosed |
| EP-3611164-A1 | PYRIDONE COMPOUND, AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE HAVING THIS AS ACTIVE COMPONENT | Mitsui Chemicals Agro, Inc. (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| CN-101547890-A | Catalytic asymmetric synthesis of primary amines via borane reduction of oxime ethers using spiroborate esters | INTELLECTUAL PROPERTY AND TECH (US) | 2009-09-30 | — | — | CN | disclosed |
| EP-2061748-A2 | CATALYTIC ASYMMETRIC SYNTHESIS OF PRIMARY AMINES VIA BORANE REDUCTION OF OXIME ETHERS USING SPIROBORATE ESTERS | Office Of Intellectual Property And Technology (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080255364-A1 | Method For The Production A-Chloroalkylpyridyl Ketones And/Or The Hydrochlorides Thereof | BASF AKTIENGESELLSCHAFT (DE) | 2008-10-16 | — | — | US | disclosed |
| WO-2008027740-A2 | CATALYTIC ASYMMETRIC SYNTHESIS OF PRIMARY AMINES VIA BORANE REDUCTION OF OXIME ETHERS USING SPIROBORATE ESTERS | OFFICE OF INTELLECTUAL PROPERTY AND TECHNOLOGY (US) | 2008-03-06 | — | — | WO | disclosed |
| EP-1343497-A1 | $g(D)?2 ,-1,2,3-TRIAZOLINE ANTICONVULSANTS AND THEIR ACTIVE METABOLITE ANALOGUES, THE AMINOALKYLPYRIDINES, ARE EXCITATORY AMINO ACID ANTAGONISTS AND ANTIISCHEMIC AGENTS, USEFUL IN THE TREATMENT OF CEREBRAL ISCHEMIA RESULTING FROM STROKE | K and K Biosciences, Inc. (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20020111371-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCES, INC. | 2002-08-15 | — | — | US | disclosed |
| WO-2002036119-A1 | Δ2,-1,2,3-TRIAZOLINE ANTICONVULSANTS AND THEIR ACTIVE METABOLITE ANALOGUES, THE AMINOALKYLPYRIDINES, ARE EXCITATORY AMINO ACID ANTAGONISTS AND ANTIISCHEMIC AGENTS, USEFUL IN THE TREATMENT OF CEREBRAL ISCHEMIA RESULTING FROM STROKE | K AND K BIOSCIENCES, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| EP-0805681-A4 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0805681-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022775-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1996-08-01 | — | — | WO | disclosed |
| EP-0299277-B1 | Process for the preparation of substituted pyridyl-alkyl ketones | BAYER AG (DE) | 1995-10-18 | — | — | EP | disclosed |
| EP-0299277-A2 | Process for the preparation of substituted pyridyl-alkyl ketones | BAYER AG (DE) | 1989-01-18 | — | — | EP | disclosed |
| EP-0299277-A2 | Process for the preparation of substituted pyridyl-alkyl ketones | BAYER AG (DE) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD3, BRD1 | CES2 3199/4885CES1 2963/4885LMNA 1185/4885 |
| US-20080255364-A1 | Method For The Production A-Chloroalkylpyridyl Ketones And/Or The Hydrochlorides Thereof | CBS, PCCA, ALK | CES2 603/4885CES1 555/4885LMNA 452/4885 |
| US-20020111371-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | CES2 1520/4885CES1 2037/4885LMNA 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.